Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022 NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on recent FDA feedback and ongoing interactions Clinical expansion efforts underway for elamipretide in rare metabolic cardiomyopathies and in rare mitochondrial disease caused by nuclear DNA mutations Pipeline development ongoing with SBT-272, SBT-550, and other pipeline compounds Management to host conference call today at 8:30am ET News provided by Share this article Share this article BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2020 and announced recent business highlights.